International regulations on mutagenic impurities and nitrosamines in medicines have entered a phase of increased technical stringency. They focus especially on nitrosamines and NDSRI compounds (Nitrosamine Derived from Substances Related to the Active Pharmaceutical Ingredient), due to health risks and widespread drug recalls in recent years.
What nitrosamines are and why they are dangerous
Nitrosamines are potentially carcinogenic chemical compounds that can form during:
- Drug synthesis.
- Drug storage.
- Interaction between excipients.
They were first detected in antihypertensives of the sartan class and later in other drugs such as ranitidine and metformin. This forced the industry to review manufacturing processes and implement systematic risk assessment programs.
New toxicological limits and evaluation criteria
European and U.S. regulatory agencies have updated guidelines on mutagenic impurities and nitrosamines, applying the principle of “as low as reasonably achievable”.
For simple nitrosamines, limits are calculated as an acceptable daily intake based on carcinogenicity studies in animals and statistical models. These values are usually expressed in nanograms per day.
The challenge increases with NDSRI, formed when a secondary or tertiary amine of the drug reacts with nitrosating agents. Their evaluation requires:
- Structural analogy.
- Predictive mutagenicity models.
- Complementary studies when necessary.
Impact on the pharmaceutical industry
Regulatory tightening requires companies to review their entire supply chain, including:
- Raw materials and solvents.
- Synthesis processes.
- Storage conditions.
- Potential cross-contamination.
Analytical controls now need to detect impurities at parts-per-billion levels, using techniques such as high-resolution mass spectrometry coupled with liquid chromatography, tailored to each active ingredient.
This entails investments in equipment, method validation, and updates to regulatory dossiers.
Scientific evaluation of NDSRI
Identification of NDSRI presents unique challenges:
- Many compounds lack complete toxicological data.
- Specific limits are applied based on chemical structure and ICH M7 guidelines on mutagenic impurities.
- Computational models for genotoxic prediction are used, and Ames tests are conducted if needed.
This approach ensures a conservative and scientifically supported evaluation, and regulatory trends are moving toward requiring more justification for setting upper limits.
Implications for quality control
Pharmaceutical quality control has evolved significantly:
- Comprehensive documentation of risk assessments.
- Drug-specific mitigation plans.
- Elimination of nitrosating agents and strict selection of raw materials.
- Packaging improvements to prevent degradation.
- Post-marketing surveillance to detect nitrosamines.
The current framework seeks a balance between patient safety and technical feasibility, although tolerance limits are now much stricter than in the past.
Frequently Asked Questions
- What are mutagenic impurities and nitrosamines?
They are chemical compounds that can cause genetic mutations and have carcinogenic potential. They are generated during synthesis, storage, or interaction among drug components. - Why are NDSRI particularly concerning?
Because they are nitrosamines derived from the active pharmaceutical ingredient itself. Their structure may not be well documented, making toxicological evaluation difficult. - How are these impurities controlled in the pharmaceutical industry?
Through advanced analyses such as liquid chromatography and mass spectrometry, review of raw materials and processes, and predictive toxicity models. - What limits are set for nitrosamines?
They are defined as acceptable daily intake (ADI), generally in nanograms per day, based on animal carcinogenicity studies and statistical models. - What measures should pharmaceutical laboratories take?
Update quality control protocols, document risk assessments, implement mitigation plans, and ensure post-marketing surveillance.
